1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  3. PPAR
  4. PPARα Isoform

PPARα

 
Cat. No. Product Name Effect Purity
  • HY-14649
    Retinoic acid
    Agonist 99.81%
    Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
  • HY-16578
    GW9662
    Antagonist 99.79%
    GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
  • HY-13956
    Pioglitazone
    Activator 99.89%
    Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research.
  • HY-17356
    Fenofibrate
    Agonist 99.92%
    Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
  • HY-15372
    GW6471
    Antagonist 99.64%
    GW6471 is a potent PPARα antagonist.
  • HY-121389
    Hexadecanamide
    Activator
    Hexadecanamide (Palmitamide), a fatty acid amide, has orally active anti-allergic, antioxidant, and neuroprotective effects. Hexadecanamide alleviate S. aureus-caused mastitis by depressing inflammatory response and maintaining blood-milk barrier integrity. Hexadecanamide depresses S. aureus-induced activation of the NF-κB pathway in mouse mammary epithelial cells (MMECs). Hexadecanamide activates PPARα. Hexadecanamide enhances sperm motility in vitro.
  • HY-115357
    BMS711939
    Agonist
    BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides.
  • HY-162963
    PPARδ agonist 11
    Agonist
    PPARδ agonist 11 (Compound 11) is a selective agonist for PPARδ with an EC50 of 20 nM. PPARδ agonist 11 reduces the levels of nitrite oxide (NO), proinflammatory cytokines TNFα and IL-6 in LPS (HY-D1056)-stimulated RAW264.7 cell, and exhibits anti-inflammatory efficacy via NF-κB pathway. PPARδ agonist 11 exhibits good stability in human liver microsomes and plasma. PPARδ agonist 11 ameliorates Carrageenan (HY-125474)-induced foot edema.
  • HY-16995
    Pirinixic acid
    Agonist 99.80%
    Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
  • HY-13202
    T0070907
    Antagonist 99.98%
    T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.
  • HY-N0019
    Daidzein
    Activator 99.72%
    Daidzein is a soy isoflavone, which acts as a PPAR activator.
  • HY-N0014
    Icariin
    Activator 99.06%
    Icariin is a flavonol glycoside. Icariin inhibits PDE5 and PDE4 activities with IC50s of 432 nM and 73.50 μM, respectively. Icariin also is a PPARα activator.
  • HY-13861
    GW7647
    Agonist 99.53%
    GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
  • HY-16737
    Elafibranor
    Agonist 99.13%
    Elafibranor (GFT505) is a PPARα agonist with EC50s of 45 and 175 nM, respectively.
  • HY-B0637
    Bezafibrate
    Agonist 99.83%
    Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
  • HY-14601
    Pioglitazone hydrochloride
    Agonist 99.97%
    Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
  • HY-N2302
    Fucoxanthin
    Inhibitor 99.47%
    Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
  • HY-13928
    GW0742
    Agonist 99.94%
    GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
  • HY-107542
    Oleoylethanolamide
    Agonist 99.94%
    Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.
  • HY-B0258
    Gemfibrozil
    Activator 99.91%
    Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.
Cat. No. Product Name / Synonyms Species Source